Cybin (OTCMKTS:CYBN) Trading Down 4.3% – Here’s Why

Cybin Inc. (OTCMKTS:CYBN) shares dropped 4.3% during mid-day trading on Wednesday . The stock traded as low as $10.20 and last traded at $10.25. Approximately 204,600 shares were traded during mid-day trading, an increase of 10% from the average daily volume of 186,805 shares. The stock had previously closed at $10.71.

Cybin Stock Down 4.3 %

The company has a market cap of $204.92 million, a price-to-earnings ratio of -1.54 and a beta of 0.38. The stock’s 50-day simple moving average is $10.19 and its 200 day simple moving average is $3.74.

Cybin Company Profile

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.